Treating hyperkalaemia with Lokelma more than doubled the odds (by ~2.5 times) of patients maintaining guideline RAASi therapy versus no potassium binder treatment.

Renal patients who stopped RAASi therapy had a 73% higher risk of progression to end-stage kidney disease within 6 months.